Effects of natalizumab treatment on Foxp3+ T regulatory cells.
about
Regulatory T cells in autoimmune neuroinflammationTherapeutic interference with leukocyte recirculation in multiple sclerosis.Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4.Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanismNatalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.The role of regulatory T cells in neurodegenerative diseases.Targeting cells in motion: migrating toward improved therapies.A changing treatment landscape for multiple sclerosis: challenges and opportunities.Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients.VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.Immunological and clinical consequences of treating a patient with natalizumab.Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q26825063-D15AEA1B-8F85-4A4E-BF60-3F107519E1A6Q30884219-4B0F6AF1-93D7-408F-A201-196F5BA60872Q31108462-8F8EF422-37C9-4155-AD57-DC8586B33C9BQ33769952-F7BA9A5E-0A77-4048-8681-C300954508C4Q33975585-FE20C7FF-1401-4C24-A326-6FEDDFBCF8F1Q34975230-D6910F6D-4655-4737-A9EA-078EC72B340FQ35061290-6CBEC536-2ACB-4203-B439-238EA16BFC87Q35163712-45BB5031-007B-46A3-8385-C1BD3E7D1871Q37213706-963B4246-D9FB-4328-A53D-3D18F6C0E3A3Q37286272-862BAC37-CA77-4352-90C4-85247401DE74Q38035240-73FD96EC-1868-42D5-877E-F2465425AA3AQ38098493-A98072FE-3992-4D2F-916C-4388F647D2EAQ38180166-9D476AD8-7D62-467A-807A-E0CF89168023Q41869890-460BC214-CAA0-4A37-8455-DE6F98E5453FQ41966039-306CE5F3-FD18-4201-B646-B0790D4A3A0FQ48439552-F0BAD269-3B98-4165-8D6F-81079994CB64Q48906242-D6129584-318B-4B48-897A-2FA05AD904F2Q48932547-5042B722-E93C-44EE-80F2-9768E2B89CB1Q50898570-DCC6FA21-FDC7-4EEA-B96B-72769C17D0ACQ58555322-95EE1B0A-3053-406E-AB47-1F2AAF8900E6
P2860
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@ast
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@en
type
label
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@ast
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@en
prefLabel
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@ast
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@en
P2093
P2860
P50
P1433
P1476
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
@en
P2093
Anne Waschbisch
Klaus V Toyka
Max-Philipp Stenner
Sebastian Doerck
P2860
P356
10.1371/JOURNAL.PONE.0003319
P407
P577
2008-10-06T00:00:00Z